The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLII.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Wada H, Nakano Y, Yamada H, Saiga T, Yamanaka A, Sakai N

Intravesical mitomycin-C-induced interstitial pneumonia.

Respiration; international review of thoracic diseases 2010;80;256-9 — 2010 — 256-9

Torra R, Poch E, Torras A, Bombí JA, Revert L

Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy.

Chemotherapy 1993 Nov-Dec;39;453-6 — 1993 Nov-Dec — 453-6

Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazze L, Schein PS

Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989 Jun;7;781-9 — 1989 Jun — 781-9